Bethesda V nodule with NIFTP correction and molecular rescue, microcarcinoma surveillance by contract, and central-neck indication arithmetic

Model answer

(A) The 2 cm Bethesda V nodule — pattern, corrected category, molecular rescue (4 marks). Stratify by pattern with prices: network ranks ACR TI-RADS first (64-77/82-90 at best thresholds) while head-to-head ATA sensitivity 95.0% costs 51.2% unnecessary biopsies against ACR 80.2/25.8% — with 7.6% off-pattern at 10.1% risk.^[11][12] Categorise with NIFTP correction: pooled Bethesda runs 97/50.7 with indeterminate 27/31% — but reclassification cuts all categories except I (V minus 16 absolute, III minus 32 relative) with surgical V/VI carrying 14/3% NIFTP — so her V is 14% NIFTP until proven otherwise.^{[14][15][17][21]} Rescue indeterminate-or-suspicious with molecular testing: randomised RNA/DNA-RNA at 80/85% specific avoids surgery in 51/49% at 20% prevalence — globally halving surgical odds while enriching resected malignancy.^[18][20]

(B) The 9 mm microcarcinoma — Kuma arithmetic with contract terms (3 marks). Quote Kuma: 1235 patients with 8% enlargement and 3.8% migration at 10 years against surgery's 4.1/0.6 palsy, 16.7/2.8 temporary hypo and 1.6/0.08 permanent hypo — with 30-year confirmation (3.8/0.8) and conversion surgery at 0.6 vs 0.7%.^[40][44][45] Quote replication: Korea 14% enlarge with volume-only detection and 0.5% migration; multicentre 9.6% composite — with immediate surgery mandated for nodes, distant spread, cord invasion, tracheal protrusion, adherence or cord-course location.^[42][43][47] Quote the honesty: 28.6% lost at 5 years (HR 1.62) with zero deaths among the lost — framed by half the incidence rise being microcarcinoma with 1-5% recurrence against 1-3% surgical harm.^[46][41]

(C) The cN0 cancer — extent, ablation, neck by numbers (3 marks). Resect by equivalence: matched microcarcinoma ties death and recurrence with lobe complications discounted — multifocal 3.15/0.78 ns with hypo 0/8.6 — lateral-node lobe ties (HR 1.03/RR 1.10) — completion falling 51.8 to 43.1%.^{[22][23][24][25]} Omit ablation by IoN: 504 low-risk at 97.9 vs 96.3% with 0.5-point difference — dose already halved by HiLo (5.9/7.3 at 7 years) and pools (OR 0.93/0.66).^{[26][27][28][29]} Dissect by indication: pooled recurrence OR 1.05 ns / RR 0.59 ns (NNT 31) / RR 0.66 significant / OR 0.65 with hypo doubled — occult nodes in half — restraint under 10% without survival gain — volume over 100 holding 3/2.6%.^{[30][31][32][33][34][35][38][39]}